BioSpace News Archive

Stryker (NYSE:SYK) announced that it will report financial results for first quarter of fiscal year 2024 on Tuesday, April 30, 2024.

Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10" or the “Company”), an agricultural bioscience company, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB) today reported results for the fourth quarter and full year ended December 31,2023.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted an aggregate of 79,800 restricted stock units to five newly-hired employees.

Acorda Therapeutics, Inc. announced that it will no longer hold its fourth quarter and year end 2023 earnings conference call originally scheduled for Monday, April 1 at 4:30 p.m. ET.

ProMIS Neurosciences Inc., a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis and multiple system atrophy, announced financial results for the fiscal year ended December 31, 2023 and provided a corporate update.

HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB) today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023.

Rapafusyn Pharmaceuticals is pleased to announce two upcoming presentations at Cambridge Health Institute’s 12th Annual Oral Peptides & Macrocyclics Conference, April 1 – 4 in San Diego.

Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.

Tango Therapeutics, Inc. announced that, effective April 1, 2024, the Compensation Committee of Tango Therapeutics’ Board of Directors granted a non-qualified stock option to purchase 139,453 shares of its common stock and 23,698 restricted stock units to a new employee under Tango Therapeutics’ 2023 Inducement Plan.